The global DTaP vaccine market is anticipated to grow at a significant CAGR of 6.5% during the forecast period 2022-2028. The major factor which is attributed to the market growth is the increased awareness among people for vaccination against Diphtheria, Tetanus and acellular Pertussisdiseases. The rise in cases of diphtheria, acellular pertussis, andtetanus is constantly being seen. As per CDC, globally there are an estimated 24.1 million cases of pertussis and about 160,700 deaths per year. Moreover, around half of babies less than 1 year old who get pertussis need treatment in the hospital due to which the demand for DTap vaccines are high.The major players in the global DTaP vaccine market are going for collaborations and mergers in order to develop new vaccines and medications. For Instance, in March 2021, Stablepharma Ltd. announced a collaboration with European vaccine manufacturer BB-NCIPD to develop a thermally stable version of the tetanus-diphtheria (Td) vaccine using the patented StablevaX formulation and device.
Browse the full report description of “Global DTaP Vaccine Market Size, Share, and Trends Analysis Report by Disease Type (Diphtheria, Tetanus, and Pertussis) and by End User (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/dtap-vaccine-market
Besides, in February 2022, Pharmaniaga Berhad signed Memoranda of Understanding (MoU) with two biotechnology companies based in Thailand for vaccine research & development (R&D) and bioequivalence solutions as well as pharmaceutical products development innovation.
Furthermore, in February 2021, Dynavax Technologies Corp. and Serum Institute of India (SIIPL), jointly announced that the first participant has been dosed in Phase 1 clinical trial evaluating tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine candidate adjuvanted with CpG 1018.
Apart from these, in February 2021, Dynavax and Serum Institute of India (SIIPL) collabooratedto develop an adjuvanted Tdap vaccine to address the shortcomings of the currently marketed acellular pertussis vaccines. Under the collaboration, Dynavax has exclusive worldwide rights to commercialize the vaccine, except that SII has exclusive rights to distribute in India and to fulfil WHO/UNICEF tender contracts. The parties are responsible for clinical development costs in their respective territories.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Disease Type
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape - Pfizer, Inc., Sanofi S.A., Novartis International AG, Bharat Biotech Ltd., and GlaxoSmithKline PLC among others
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global DTaP Vaccine Market Report Segment
By Disease Type
By End-User
Global DTaP Vaccine Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/anti-suicidal-drugs-market